tiprankstipranks
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market
DMAC
Diamedica Therapeutics
RESEARCH TOOLSreports
Want to see DMAC full AI Analyst Report?

Diamedica Therapeutics (DMAC) Stock Forecast & Price Target

569 Followers
See the Price Targets and Ratings of:

DMAC Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Diamedica
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DMAC Stock 12 Month Forecast

Average Price Target

$17.00
▲(148.18% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Diamedica Therapeutics in the last 3 months. The average price target is $17.00 with a high forecast of $25.00 and a low forecast of $12.00. The average price target represents a 148.18% change from the last price of $6.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,7.849230769230769,9.278461538461539,10.707692307692307,12.136923076923075,13.566153846153846,14.995384615384614,16.424615384615386,17.853846153846153,19.28307692307692,20.71230769230769,22.14153846153846,23.57076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,7.233846153846153,8.047692307692309,8.861538461538462,9.675384615384615,10.489230769230769,11.303076923076922,12.116923076923078,12.930769230769231,13.744615384615384,14.558461538461538,15.372307692307693,16.186153846153847,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,6.849230769230769,7.2784615384615385,7.707692307692308,8.136923076923077,8.566153846153846,8.995384615384616,9.424615384615384,9.853846153846154,10.283076923076923,10.712307692307693,11.141538461538461,11.57076923076923,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$17.00Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DMAC
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$12
Buy
75.18%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (NASDAQ: DMAC), Xtant Medical Holdings (NYSE MKT: XTNT) and Accendra Health (NYSE: ACH)
Lake Street Analyst forecast on DMAC
Thomas Flaten
Lake Street
Lake Street
$14
Buy
104.38%
Upside
Reiterated
04/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (NASDAQ: DMAC), Elevance Health (NYSE: ELV) and Oric Pharmaceuticals (NASDAQ: ORIC)
Craig-Hallum Analyst forecast on DMAC
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on DMAC
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$25
Buy
264.96%
Upside
Reiterated
01/21/26
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)
TD Cowen Analyst forecast on DMAC
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Initiated
10/30/25
Buy Rating for Diamedica Therapeutics: Promising Potential of DM199 in Preeclampsia Treatment
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DMAC
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$12
Buy
75.18%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (NASDAQ: DMAC), Xtant Medical Holdings (NYSE MKT: XTNT) and Accendra Health (NYSE: ACH)
Lake Street Analyst forecast on DMAC
Thomas Flaten
Lake Street
Lake Street
$14
Buy
104.38%
Upside
Reiterated
04/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (NASDAQ: DMAC), Elevance Health (NYSE: ELV) and Oric Pharmaceuticals (NASDAQ: ORIC)
Craig-Hallum Analyst forecast on DMAC
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on DMAC
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$25
Buy
264.96%
Upside
Reiterated
01/21/26
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)
TD Cowen Analyst forecast on DMAC
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Initiated
10/30/25
Buy Rating for Diamedica Therapeutics: Promising Potential of DM199 in Preeclampsia Treatment
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Diamedica Therapeutics

3 Months
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+19.93%
reiterated a xxx
 rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +19.93% per trade.
1 Year
Chase KnickerbockerCraig-Hallum
Success Rate
14/16 ratings generated profit
88%
Average Return
+28.68%
reiterated a buy rating 22 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +28.68% per trade.
2 Years
xxx
Success Rate
14/16 ratings generated profit
88%
Average Return
+58.49%
reiterated a xxx
 rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +58.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DMAC Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Mar 26
Apr 26
Strong Buy
4
3
5
3
5
Buy
3
4
3
4
2
Hold
0
1
25
32
40
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
33
39
47
In the current month, DMAC has received 7 Buy Ratings, 40 Hold Ratings, and 0 Sell Ratings. DMAC average Analyst price target in the past 3 months is 17.00.
Each month's total comprises the sum of three months' worth of ratings.

DMAC Financial Forecast

DMAC Earnings Forecast

The previous quarter’s earnings for DMAC were -$0.17.
The previous quarter’s earnings for DMAC were -$0.17.
No data currently available

DMAC Sales Forecast

The previous quarter’s earnings for DMAC were $0.00.
The previous quarter’s earnings for DMAC were $0.00.

DMAC Stock Forecast FAQ

What is DMAC’s average 12-month price target, according to analysts?
Based on analyst ratings, Diamedica Therapeutics Inc’s 12-month average price target is 17.00.
    What is DMAC’s upside potential, based on the analysts’ average price target?
    Diamedica Therapeutics Inc has 148.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DMAC a Buy, Sell or Hold?
          Diamedica Therapeutics Inc has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Diamedica Therapeutics Inc’s price target?
            The average price target for Diamedica Therapeutics Inc is 17.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $12.00. The average price target represents 148.18% Increase from the current price of $6.85.
              What do analysts say about Diamedica Therapeutics Inc?
              Diamedica Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of DMAC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.